These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26354966)

  • 1. Optimal Usage of Colistin: Are We Any Closer?
    Pogue JM; Ortwine JK; Kaye KS
    Clin Infect Dis; 2015 Dec; 61(12):1778-80. PubMed ID: 26354966
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic Use.
    Nation RL; Forrest A
    Adv Exp Med Biol; 2019; 1145():219-249. PubMed ID: 31364081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
    Zavascki AP; Nation RL
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymyxin B versus colistin: an update.
    Cai Y; Lee W; Kwa AL
    Expert Rev Anti Infect Ther; 2015; 13(12):1481-97. PubMed ID: 26488563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
    Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
    Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.
    Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC
    Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
    Evans ME; Feola DJ; Rapp RP
    Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study.
    Aggarwal R; Dewan A
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):15. PubMed ID: 29571295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
    Kassamali Z; Jain R; Danziger LH
    Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxin B: similarities to and differences from colistin (polymyxin E).
    Kwa A; Kasiakou SK; Tam VH; Falagas ME
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing use of colistin and polymyxin B in the critically ill.
    Nation RL; Li J
    Semin Respir Crit Care Med; 2007 Dec; 28(6):604-14. PubMed ID: 18095224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
    Vardakas KZ; Falagas ME
    Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the Individual Major Components of Polymyxin B and Colistin in Rats.
    Sivanesan S; Roberts K; Wang J; Chea SE; Thompson PE; Li J; Nation RL; Velkov T
    J Nat Prod; 2017 Jan; 80(1):225-229. PubMed ID: 28080060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
    Kassamali Z; Danziger L
    Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility testing of the polymyxins: where are we now?
    Humphries RM
    Pharmacotherapy; 2015 Jan; 35(1):22-7. PubMed ID: 25329490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifications in the pmrB gene are the primary mechanism for the development of chromosomally encoded resistance to polymyxins in uropathogenic Escherichia coli.
    Phan MD; Nhu NTK; Achard MES; Forde BM; Hong KW; Chong TM; Yin WF; Chan KG; West NP; Walker MJ; Paterson DL; Beatson SA; Schembri MA
    J Antimicrob Chemother; 2017 Oct; 72(10):2729-2736. PubMed ID: 29091192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?
    Giacobbe DR; Karaiskos I; Bassetti M
    Expert Opin Pharmacother; 2022 Jan; 23(1):5-8. PubMed ID: 34399631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.